Advancing malaria treatment with magnetic and mesoporous silica nanoparticles loaded with sulfadoxine-pyrimethamine: a review
Source abstract
Abstract
Malaria remains a pressing global health concern, particularly in regions with rising cases of drug-resistant Plasmodium strains. Sulphadoxine-pyrimethamine (SP), a widely used antimalarial drug combination, faces challenges such as reduced bioavailability, systemic toxicity, and diminished efficacy due to resistance. In response, nanotechnology offers innovative strategies to improve SP delivery and therapeutic outcomes. This review focuses on the potential of magnetic and mesoporous silica nanoparticles as advanced drug delivery platforms for SPs. Magnetic and mesoporous silica nanoparticles combine a magnetic core, enabling targeted delivery through external magnetic fields, with a mesoporous silica shell that allows high drug loading and controlled release. This review explores recent advancements in magnetic and mesoporous silica nanoparticles synthesis, surface functionalization, and drug encapsulation techniques, highlighting their ability to increase SP bioavailability, ensure sustained drug release, and minimize off-target effects. In vitro and in vivo studies have demonstrated the improved pharmacokinetics, reduced toxicity, and enhanced antimalarial efficacy of SP-loaded magnetic and mesoporous silica nanoparticles, particularly against resistant Plasmodium strains. Additionally, the versatility of magnetic and mesoporous silica nanoparticles paves the way for the codelivery of synergistic drugs and the development of theranostic systems. While magnetic and mesoporous silica nanoparticles show immense promise, challenges such as scalability, biocompatibility, and regulatory hurdles must be addressed to facilitate clinical translation. By bridging nanotechnology with malaria treatment, this approach has the potential to revolutionize antimalarial therapy, providing a scalable and effective solution for resource-limited settings.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Malaria Research and Control · Nanoparticle-Based Drug Delivery · Nanoparticles: synthesis and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. World Health Organization. (2024). Malaria fact sheet. Retrieved from https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024
2. Public Health Weekly Report. (2024). 17(32), 1351–1377. https://doi.org/10.56786/PHWR.2024.17.32.110.56786/PHWR.2024.17.32.1 ↗
3. Halliday KE, Witek-McManus SS, Opondo C, Mtali A, Allen E, Bauleni A, Ndau S, Phondiwa E, Ali D, Kachigunda V, Sande JH, Jawati M, Verney A, Chimuna T, Melody D, Moestue H, Roschnik N, Brooker SJ, Mathanga DP. Impact of school-based malaria case management on school attendance, health and education outcomes: a cluster randomised trial in southern Malawi. BMJ Glob Health. 2020. https://doi.org/10.1136/bmjgh-2019-001666.10.1136/bmjgh-2019-001666 ↗
4. Wells TNC, van Huijsduijnen RH, Van Voorhis WC. Malaria medicines: a glass half full? Nat Rev Drug Discov. 2015;14(6):424–42. https://doi.org/10.1038/nrd4573.10.1038/nrd4573 ↗
5. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361(5):455–67. https://doi.org/10.1056/NEJMoa0808859.10.1056/NEJMoa0808859 ↗
6. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. Lancet. 2014;383(9918):723–35. https://doi.org/10.1016/S0140-6736(13)60024-0.10.1016/S0140-6736(13)60024-0 ↗
7. Sinha S, Medhi B, Sehgal R. Challenges of drug-resistant malaria. Parasite. 2014;21:61. https://doi.org/10.1051/parasite/2014059.10.1051/parasite/2014059 ↗
8. Hanboonkunupakarn B, Tarning J, Pukrittayakamee S, Chotivanich K. Artemisinin resistance and malaria elimination: where are we now? Front Pharmacol. 2022;13: 876282. https://doi.org/10.3389/fphar.2022.876282.10.3389/fphar.2022.876282 ↗
9. Kankala RK, Han YH, Xia HY, Wang SB, Chen AZ, Zou DY. Nanoarchitectured prototypes of mesoporous silica nanoparticles for innovative biomedical applications. J Nanobiotechnol. 2022. https://doi.org/10.1186/s12951-022-01315-x.10.1186/s12951-022-01315-x ↗
10. Majid, A., Ahmed, W., Patil Sen, Y., & Sen, T. Synthesis and characterization of magnetic nanoparticles in medicine. In M. J. Jackson & W. Ahmed (Eds.), Micro and Nanomanufacturing (2018); Volume II, 413–442. Springer. https://doi.org/10.1007/978-3-319-67132-1_1410.1007/978-3-319-67132-1_14 ↗
11. Gupta J, Quadros M, Momin M. Mesoporous silica nanoparticles: Synthesis and multifaceted functionalization for controlled drug delivery. J Drug Deliv Sci Technol. 2023;81: 104305. https://doi.org/10.1016/j.jddst.2023.104305.10.1016/j.jddst.2023.104305 ↗
12. de Andrade R, Schmidt RD, Gomes LS, Colina-Vegas L, Hinrichs R, Vasconcellos MA, Costa TM, Deon M, Villarreal W, Benvenutti EV. Magnetic mesoporous silica for targeted drug delivery of chloroquine: synthesis, characterization, and in vitro evaluation. Pharmaceutics. 2024;16(3):357. https://doi.org/10.3390/pharmaceutics16030357.10.3390/pharmaceutics16030357 ↗
13. Amolegbe SA, Hirano Y, Adebayo JO, Ademowo OG, Balogun EA, Obaleye JA, Hayami S. Mesoporous silica nanocarriers encapsulated antimalarials with high therapeutic performance. Sci Rep. 2018;8:3061. https://doi.org/10.1038/s41598-018-21351-8.10.1038/s41598-018-21351-8 ↗
14. Wang X, Xie Y, Jiang N, Wang J, Liang H, Liu D, Yang N, Sang X, Feng Y, Chen R, Chen Q. Enhanced antimalarial efficacy obtained by targeted delivery of artemisinin in heparin-coated magnetic hollow mesoporous nanoparticles. ACS Appl Mater Interfaces. 2021;13(1):287–97. https://doi.org/10.1021/acsami.0c20070.10.1021/acsami.0c20070 ↗
15. Ali A, Zafar H, Zia M, Ul Haq I, Phull AR, Ali JS, Hussain A. Synthesis, characterization, applications, and challenges of iron oxide nanoparticles. Front Chem. 2021;9: 629054. https://doi.org/10.3389/fchem.2021.629054.10.3389/fchem.2021.629054 ↗
16. Alven S, Aderibigbe B. Combination therapy strategies for the treatment of malaria. Molecules. 2019;24(19):3601. https://doi.org/10.3390/molecules24193601.10.3390/molecules24193601 ↗
17. Hyde JE. Targeting purine and pyrimidine metabolism in human apicomplexan parasites. Curr Drug Targets. 2007;8(1):31–47. https://doi.org/10.2174/138945007779315524.10.2174/138945007779315524 ↗
18. Nzila AM, Mberu EK, Sulo J, Dayo H, Winstanley PA, Sibley CH, Watkins WM. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: Genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites (2000). Antimicrobial Agents Chemother. 2000;44(4):991–6. https://doi.org/10.1128/aac.44.4.991-996.2000.10.1128/aac.44.4.991-996.2000 ↗
19. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mbreu EK, Cowman AF, Winstanley PA, Watkins WM, Nzila AM. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol. 2001;17(12):582–528. https://doi.org/10.1016/s1471-4922(01)02085-2.10.1016/s1471-4922(01)02085-2 ↗
20. National Center for Biotechnology Information (NCBI). (n.d.). PubChem Compound Summary for CID 4993, Pyrimethamine. https://pubchem.ncbi.nlm.nih.gov/compound/4993
21. National Center for Biotechnology Information (NCBI). (n.d.). PubChem Compound Summary for CID 5320, Sulfadoxine. https://pubchem.ncbi.nlm.nih.gov/compound/5320
22. Triglia T., Wang P., Sims P.F.G., Hyde J.E. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proceedings of the National Academy of Sciences USA. 1997;94(25):13944 13949. https://doi.org/10.1073/pnas.94.25.1394410.1073/pnas.94.25.13944 ↗
23. De Oliveira LF, et al. Magnetic mesoporous silica nanoparticles for chloroquine delivery: synthesis, characterization, and biocompatibility. Pharmaceutics. 2024;16(3):357. https://doi.org/10.3390/pharmaceutics16030357.10.3390/pharmaceutics16030357 ↗
24. Tao C, Zhu Y. Magnetic mesoporous silica nanoparticles for potential delivery of chemotherapeutic drugs and hyperthermia. Dalton Trans. 2014;43(41):15482–90. https://doi.org/10.1039/C4DT01984A.10.1039/C4DT01984A ↗
25. Alker AP, Mwapasa V, Purfield A, Rogerson SJ, Molyneux ME, Kamwendo DD, Meshnick SR. Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre. Malawi Antimicrobial Agents Chemotherapy. 2005;49(9):3919–21. https://doi.org/10.1128/aac.49.9.3919-3921.2005.10.1128/aac.49.9.3919-3921.2005 ↗
26. Sundararaman SA, Odom John AR. Prevention of malaria in pregnancy: the threat of sulfadoxine-pyrimethamine resistance. Front Pediatr. 2022;10: 966402. https://doi.org/10.3389/fped.2022.966402.10.3389/fped.2022.966402 ↗
27. de Kock M, Tarning J, Workman L, Allen EN, Tekete MM, Djimde AA, Denti P. Population pharmacokinetic properties of sulfadoxine and pyrimethamine: a pooled analysis to inform optimal dosing in African children with uncomplicated malaria. Antimicrob Agents Chemother. 2018;62(5):10–1128. https://doi.org/10.1128/aac.01370-17.10.1128/aac.01370-17 ↗
28. Shibeshi MA, Kifle ZD, Atnafie SA. Antimalarial drug resistance and novel targets for antimalarial drug discovery. Infect Drug Resist. 2020;13:4047–60. https://doi.org/10.2147/IDR.S279433.10.2147/IDR.S279433 ↗
29. Fatima R, Katiyar P, Kushwaha K. Recent advances in mesoporous silica nanoparticle: synthesis, drug loading, release mechanisms, and diverse applications. Front Nanotechnol. 2025;7:1564188. https://doi.org/10.3389/fnano.2025.1564188.10.3389/fnano.2025.1564188 ↗
30. Kianfar E. Magnetic nanoparticles in targeted drug delivery: a review. J Supercond Nov Magn. 2021;34:1709–35. https://doi.org/10.1007/s10948-021-05932-9.10.1007/s10948-021-05932-9 ↗
31. Kekani LN, Witika BA. Current advances in nanodrug delivery systems for malaria prevention and treatment. Discover Nano. 2023;18(1):66. https://doi.org/10.1186/s11671-023-03849-x.10.1186/s11671-023-03849-x ↗
32. Deshmukh R, Dewangan B, Harwansh RK, Agrawal R, Garg A, Chopra H. Current trends in nanotechnology-based drug delivery systems for the diagnosis and treatment of malaria: a review. Curr Drug Deliv. 2025. https://doi.org/10.2174/0115672018291253240115012327.10.2174/0115672018291253240115012327 ↗
33. Rajwar TK, Pradhan D, Halder J, Rai VK, Kar B, Ghosh G, Rath G. Opportunity in nanomedicine to counter the challenges of current drug delivery approaches used for the treatment of malaria: a review. J Drug Target. 2023;31(4):354–68. https://doi.org/10.1080/1061186X.2022.2164290.10.1080/1061186X.2022.2164290 ↗
34. Montiel Schneider MG, Martín MJ, Otarola J, Vakarelska E, Simeonov V, Lassalle V, Nedyalkova M. Biomedical applications of iron oxide nanoparticles: current insights progress and perspectives. Pharmaceutics. 2022;14(1):204. https://doi.org/10.3390/pharmaceutics14010204.10.3390/pharmaceutics14010204 ↗
35. Arias LS, Pessan JP, Vieira APM, Lima TMTD, Delbem ACB, Monteiro DR. Iron oxide nanoparticles for biomedical applications: a perspective on synthesis, drugs, antimicrobial activity, and toxicity. Antibiotics. 2018;7(2):46. https://doi.org/10.3390/antibiotics7020046.10.3390/antibiotics7020046 ↗
36. Gautier J, Allard-Vannier E, Hervé-Aubert K, Soucé M, Chourpa I. Design strategies of hybrid metallic nanoparticles for theragnostic applications. Nanotechnology. 2013;24(43): 432002. https://doi.org/10.1088/0957-4484/24/43/432002.10.1088/0957-4484/24/43/432002 ↗
37. Salehirozveh M, Dehghani P, Mijakovic I. Synthesis, functionalization, and biomedical applications of iron oxide nanoparticles (IONPs). J Funct Biomater. 2024;15(11):340. https://doi.org/10.3390/jfb15110340.10.3390/jfb15110340 ↗
38. Dash S, Das T, Patel P, Panda PK, Suar M, Verma SK. Emerging trends in the nanomedicine applications of functionalized magnetic nanoparticles as novel therapies for acute and chronic diseases. J Nanobiotechnol. 2022;20(1):393. https://doi.org/10.1186/s12951-022-01595-3.10.1186/s12951-022-01595-3 ↗
39. Pande V, Kothawade S, Kuskar S, Bole S, Chakole D. Fabrication of mesoporous silica nanoparticles and its applications in drug delivery. In nanofabrication techniques-principles processes and applications. Intech Open. 2023;2:36. https://doi.org/10.5772/intechopen.112428.10.5772/intechopen.112428 ↗
40. Fatima R, Katiyar P, Kushwaha K. Recent advances in mesoporous silica nanoparticle: synthesis, drug loading, release mechanisms, and diverse applications. Front Nanotechnol. 2025. https://doi.org/10.3389/fnano.2025.1564188.10.3389/fnano.2025.1564188 ↗
41. Du J, Liu X, Hou Z, Liu X, Yao J, Cheng X, Wang X, Tang R. Acid-sensitive polymeric prodrug micelles for achieving enhanced chemo-phytodynamic therapy. J Drug Deliv Sci Technol. 2022;74: 103514. https://doi.org/10.1016/j.jddst.2022.103514.10.1016/j.jddst.2022.103514 ↗
42. He Q, Zhang J, Shi J, Zhu Z, Zhang L, Bu W, Guo L, Chen Y. The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins and cellular responses. Biomaterials. 2010;31(6):1085–92. https://doi.org/10.1016/j.biomaterials.2009.10.046.10.1016/j.biomaterials.2009.10.046 ↗
43. Vallet-Regi M, Colilla M, Izquierdo-Barba I, Manzano M. Mesoporous silica nanoparticles for drug delivery: current insights. Molecules. 2018;23(1):47. https://doi.org/10.3390/molecules23010047.10.3390/molecules23010047 ↗
44. Croissant GJ, Fatieiev Y, Khashab NV. Degradability and clearance of silicon, organosilica, silsesquioxane, silica mixed oxide, and mesoporous silica nanoparticles. Adv Mater. 2017;29(9):1604634. https://doi.org/10.1002/adma.201604634.10.1002/adma.201604634 ↗
45. Man-tang Q, Xiao-bing C. Biocompatibility of mesoporous silica nanoparticles. Chin J Tissue Eng Res. 2012;16(38):7156–60. https://doi.org/10.3969/j.issn.2095-4344.2012.38.026.10.3969/j.issn.2095-4344.2012.38.026 ↗
46. Arruebo M, Fernandez-Pacheco R, Ibarra MR, Santamaria J. Magnetic nanoparticles for drug delivery. Nano Today. 2007;2(3):22–32. https://doi.org/10.1016/S1748-0132(07)70084-1.10.1016/S1748-0132(07)70084-1 ↗
47. Arias LS, Pessan JP, Vieira APM, Lima TMT, Delbem ACB, Monteiro DR. Iron oxide nanoparticles for biomedical applications: a perspective on synthesis, drugs, antimicrobial activity, and toxicity. Antibiotics. 2018;7(2): 46. https://doi.org/10.3390/antibiotics7020046.10.3390/antibiotics7020046 ↗
48. Estelrich J, Sanchez-Martin MJ, Busquets MA. Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents. Int J Nanomedicine. 2015;10:1727–41. https://doi.org/10.2147/IJN.S76501.10.2147/IJN.S76501 ↗
49. Kovtareva S, Kusepova L, Tazhkenova G, Mashan T, Bazarbaeva K, Kopishev E. Surface modification of mesoporous silica nanoparticles for application in targeted delivery systems of antitumour drugs. Polymers (Basel). 2024;16(8):1105. https://doi.org/10.3390/polym16081105.10.3390/polym16081105 ↗
50. TrzecI AK, Chotera-Ouda A, Bak-Sypien I, Potrzebowski MJ. Mesoporous silica particles as drug delivery systems–The state of the art in loading methods and the recent progress in analytical techniques for monitoring these processes. Pharmaceutics. 2021;13(7):950. https://doi.org/10.3390/pharmaceutics13070950.10.3390/pharmaceutics13070950 ↗
51. Abbasi YF, Bera H, Cun D, Yang M. Recent advances in pH/enzyme-responsive polysaccharide-small-molecule drug conjugate as nanoparticles. Carbohyd Polym. 2023;312: 120797. https://doi.org/10.1016/j.carbpol.2023.120797.10.1016/j.carbpol.2023.120797 ↗
52. Malekmohammadi S, Jamshidi R, Sadowska JM, Meng C, Abeykoon C, Akbari M, Gong RH. Stimuli-responsive codelivery system-embedded polymeric nanofibers with synergistic effects of growth factors and low-intensity pulsed ultrasound to enhance osteogenesis properties. ACS Appl Bio Mater. 2024;7(7):4293–306. https://doi.org/10.1021/acsabm.4c00435.10.1021/acsabm.4c00435 ↗
53. Kovtareva SY, Kopishev EE, Zhang H, Filippov SK. Exploring the physicochemical interactions and loading strategies of mesoporous silicon dioxide nanoparticles for drug delivery. Eur J Pharm Biopharm. 2025;208: 114654.10.1016/j.ejpb.2025.114654 ↗
54. Niroumand, U., Firouzabadi, N., Goshtasbi, G., Hassani, B., Ghasemiyeh, P., & Mohammadi-Samani, S., The effect of size, morphology and surface properties of mesoporous silica nanoparticles on pharmacokinetic aspects and potential toxicity concerns. (2023)10.3389/fmats.2023.1189463 ↗
55. Luo Z, Jin K, Pang Q, Shen S, Yan L, Jiang Y, Zhao Y. Recent advancements in pH-sensitive mesoporous silica nanoparticles for cancer therapy. Acta Biomater. 2022;146:29–51. https://doi.org/10.1016/j.actbio.2022.02.013.10.1016/j.actbio.2022.02.013 ↗
56. Zhou L, Dai Y, Huang X, Yu Y, Long Y, Zhang L, Wang X. Dual pH/enzyme-responsive mesoporous silica nanoparticles for tumor-specific combination therapy. Acta Biomater. 2020;101:495–507. https://doi.org/10.1016/j.actbio.2019.11.005.10.1016/j.actbio.2019.11.005 ↗
57. Smith, L. A., Young, A. F., & Walker, S. L. Tunable PEG-drug conjugates with ester linkers for enhanced release in acidic environments. Master’s Thesis, University of Pretoria. (2023)
58. Budiman A, Rusdin A, Wardhana YW, Puluhulawa LE, CindanaMo’o FR, Thomas N, Gazzali AM, Aulifa DL. Exploring the transformative potential of functionalized mesoporous silica in enhancing antioxidant activity: a comprehensive review. Antioxidants (Basel). 2024;13(8):936. https://doi.org/10.3390/antiox13080936.10.3390/antiox13080936 ↗
59. Zhang Y, Wang J, Bai X, Jiang T, Zhang Q, Wang S. Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs. Mol Pharm. 2012;9(3):505–13. https://doi.org/10.1021/mp200287c.10.1021/mp200287c ↗
60. Siepmann J, Siepmann F. Modeling of diffusion controlled drug delivery. J Control Release. 2012;161(2):351–62. https://doi.org/10.1016/j.jconrel.2011.10.006.10.1016/j.jconrel.2011.10.006 ↗
61. Paris JL, Vallet-Regí M. Mesoporous silica nanoparticles for co-delivery of drugs and nucleic acids in cancer therapy. Nanomed: Nanotechnol, Biol Med. 2020;24:102149. https://doi.org/10.1016/j.nano.2019.102149.10.1016/j.nano.2019.102149 ↗
62. Amolegbe SA, Hirano Y, Adebayo JO, Ademowo OG, Balogun EA, Obaleye JA, Krettli AU, Yu C, Hayami S. Mesoporous silica nanocarriers encapsulated antimalarials with high therapeutic performance. Sci Rep. 2018;8(1):3078. https://doi.org/10.1038/s41598-018-21351-8.10.1038/s41598-018-21351-8 ↗
63. Wani A, Savithra GHL, Abyad A, Kanvinde S, Li J, Brock S, Oupicky D. Surface PEGylation of mesoporous silica nanorods (MSNR): effect on loading, release, and delivery of mitoxantrone in hypoxic cancer cells. Sci Rep. 2017;7(1):2274. https://doi.org/10.1038/s41598-017-02531-4.10.1038/s41598-017-02531-4 ↗
64. Rozas R, Ortiz AC, Penaloza S, Lizama S, Flores ME, Morales J, Arriagada F. Kinetics and methodological insights into hydrophilic drug release from mesoporous silica nanocarriers. Pharmaceutics. 2025;17(6):694. https://doi.org/10.1016/j.jconrel.2022.07.030.10.1016/j.jconrel.2022.07.030 ↗
65. Liu G, Li O, Ni W, Zhang N, Zheng X, Wang Y, Shao D, Tai G. Cytotoxicity of various types of gold-mesoporous silica nanoparticles in human breast cancer cells. Int J Nanomedicine. 2015;10:6075–87. https://doi.org/10.2147/IJN.S90887.10.2147/IJN.S90887 ↗
66. Lin YS, Haynes CL. Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity. J Am Chem Soc. 2010;132(14):4834–42. https://doi.org/10.1021/ja910846q.10.1021/ja910846q ↗
67. Chen ZA, Wu SH, Chen P, Chen YP, Mou CY. Critical features for mesoporous silica nanoparticles encapsulated into erythrocytes. ACS Appl Mater Interfaces. 2019;11(5):4790–8. https://doi.org/10.1021/acsami.8b18434.10.1021/acsami.8b18434 ↗
68. Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small. 2010. https://doi.org/10.1002/smll.201000538.10.1002/smll.201000538 ↗
69. Amolegbe S, Hirano Y, Adebayo JO, Ademowo OG, Balogun EA, Obaleye JA, Krettli AU, Yu C, Haymi S. Mesoporous silica nanoparticles encapsulated antimalarials with high therapeutic performance. Sci Rep. 2018;8:3078. https://doi.org/10.1038/s41598-018-21351-8.10.1038/s41598-018-21351-8 ↗
70. Gandhi S, Kamath S, Sethuraman S, Uma Maheswari K. In vivo biodistribution and pathological manifestations of iron oxide incorporated mesoporous silica: implications on its biomedical applications. J Porous Mater. 2017;24(3):1–8. https://doi.org/10.1007/s10934-016-0312-y.10.1007/s10934-016-0312-y ↗
71. Carvalho GC, Sabio RM, Ribeiro TC, Monteriro AS, Pereira DV, Ribeiro SJL, Chorilli M. Highlights in mesoporous silica nanoparticles as a multifunctional controlled drug delivery nanoplatform for infectious diseases treatment. Pharm Res. 2020;37(10):191. https://doi.org/10.1007/s11095-020-02917-6.10.1007/s11095-020-02917-6 ↗
72. Xu C, Yu S, Liu L, Wu X, Dai H. Magnetically targeted co delivery of hydrophilic and hydrophobic drugs with hollow mesoporous ferrite nanoparticles. RSC Adv. 2018;8:15326–35. https://doi.org/10.1039/C8RA02343C.10.1039/C8RA02343C ↗
73. Attia MS, Yahya A, Abdel Monaem N, Sabry SA. Mesoporous silica nanoparticles: their potential as drug delivery carriers and nanoscavengers in Alzheimer’s and Parkinson’s diseases. Saudi Pharm J. 2023;31(3):417–32. https://doi.org/10.1016/j.jsps.2023.01.009.10.1016/j.jsps.2023.01.009 ↗
74. Morales V, McConnell J, Pérez-Garnes M, Almendro N, Sanz R, García-Muñoz RA. L-Dopa release from mesoporous silica nanoparticles engineered through the concept of drug-structure-directing agents for Parkinson’s disease. J Mater Chem B. 2021;9(20):4178–89.10.1039/D1TB00481F ↗
75. Ye F, Laurent S, Fornara A, Astolfi L, Qin L, Roch A, Martini A, Toprak SM, Muller RN, Muhammed M. Uniform mesoporous silica coated iron oxide nanoparticles as a highly efficient, nontoxic MRI T2 contrast agent with tunable proton relaxivities. Contrast Media Mol Imaging. 2012;7(5):460–8. https://doi.org/10.1002/cmmi.1473.10.1002/cmmi.1473 ↗
76. Wang W, Sun X, Zhang H, Yang C, Liu Y, Yang W, Guo C, Wang C. Controlled release hydrogen sulfide delivery system based on mesoporous silica nanoparticles protects graft endothelium from ischemia–reperfusion injury. Int J Nanomedicine. 2016;11:3255–63. https://doi.org/10.2147/ijn.s104604.10.2147/ijn.s104604 ↗
77. Colilla M, Vallet-Regí M. Targeted stimuli-responsive mesoporous silica nanoparticles for bacterial infection treatment. Int J Mol Sci. 2020;21(22):8605. https://doi.org/10.3390/ijms21228605.10.3390/ijms21228605 ↗
78. Gonzalez B, Colilla M, Diez J, Pedraza D, Guembe M, Izquierdo-Barba I, Vallet-Regi M. Mesoporous silica nanoparticles decorated with polycationic dendrimers for infection treatment. Acta Biomater. 2018;68:261–71. https://doi.org/10.1016/j.actbio.2017.12.041.10.1016/j.actbio.2017.12.041 ↗
79. Feng J, Sun L, Chen W, Wei N, Hou C, Chen Z, Meng F, Cao H. Synthesis, antifungal evaluation, and safety assessment of mesoporous silica nanoparticles loaded with prothioconazole against crop pathogens. Environ Sci Nano. 2022;9:2548–58. https://doi.org/10.1039/D2EN00226D.10.1039/D2EN00226D ↗
80. Wang Y, Gu H. Core-shell-type magnetic mesoporous silica nanocomposites for bioimaging and therapeutic agent delivery. Adv Mater. 2015;27(3):576–85. https://doi.org/10.1002/adma.201401124.10.1002/adma.201401124 ↗
81. Kankala RK, Han Y-H, Na J, Lee C-H, Sun Z, Wang S-B, Kimura T, Yong SO, Yamachi Y, Chen A-Z, Wu KCW. Nanoarchitectured structured and surface biofunctionality of mesoporous silica nanoparticles. Adv Mater. 2020;32(23):1907035. https://doi.org/10.1002/adma.1907035.10.1002/adma.1907035 ↗
82. Manzano M, Regi-Vallet M. Mesoporous silica nanoparticles for drug delivery. Adv Func Mater. 2019;30(2):1902634. https://doi.org/10.1002/adfm.201902634.10.1002/adfm.201902634 ↗
83. Chen Mo, Qiao Y, CaO J, Ta L, Ci T, Ke X. Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia. J Nanobiotechnology. 2022;20:273. https://doi.org/10.1186/s12951-022-01491-w.10.1186/s12951-022-01491-w ↗
84. Kankala RK, Wang SB, Chen AZ. Nanoarchitecting hierarchical mesoporous siliceous frameworks: a new way forward. iScience. 2020;23(11):11687. https://doi.org/10.1016/j.isci.2020.101687.10.1016/j.isci.2020.101687 ↗
85. Al-Thani AN, Jan AG, Abbas M, Geetha M, Sadasivuni KK. Nanoparticles in cancer theragnostic and drug delivery: a comprehensive review. Life Sci. 2024;352:122899.10.1016/j.lfs.2024.122899 ↗
86. Fang W, Zhu W, Chen H, Zhang H, Hong S, Wei W, Zhao T. MRI enhancement and tumor-targeted drug delivery using Zn2⁺doped Fe₃O₄ core/mesoporous silica shell nanocomposites. ACS Appl Bio Mater. 2020;3(3):1690–7. https://doi.org/10.1021/acsabm.9b01244.10.1021/acsabm.9b01244 ↗
87. Grzelak J, Gazquez J, Grayston A, Teles M, Herranz F, Rohr N, Rosell A, Roig A, Gich M. Magnetic mesoporous silica nanorods loaded with ceria and functionalized with fluorophores for multimodal imaging. ACS Appl Nano Mater. 2022;5(2):2113–25. https://doi.org/10.1021/acsanm.1c03837.10.1021/acsanm.1c03837 ↗
88. Qiao Q, Xie W, Wang Y, Guo Z, Gao F, Zhao L, Cai Q. A theranostic nanocomposite system based on radial mesoporous silica hybridized with Fe3O4 nanoparticles for targeted magnetic field responsive chemotherapy of breast cancer. RSC Adv. 2018;8:4321–8. https://doi.org/10.1039/C7RA12446E.10.1039/C7RA12446E ↗
89. Zhuang J, Yu Y, Lu R. Mesoporous silica nanoparticles as carrier to overcome bacterial drug resistant barriers. Int J Pharmaceut. 2023;631: 122529. https://doi.org/10.1016/j.ijpharm.2022.122529.10.1016/j.ijpharm.2022.122529 ↗
90. Shen J, He Q, Gao Y, Shi J, Li Y. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism. Nanoscale. 2011;3(10):4314–22. https://doi.org/10.1039/c1nr10580a.10.1039/c1nr10580a ↗
91. Wang L, Guan H, Wang Z, Xing Y, Zhang J, Cai K. Hybrid mesoporous-microporous nanocarriers for overcoming multidrug resistance by sequential drug delivery. Mol Pharm. 2018;15(7):2503–12. https://doi.org/10.1021/acs.molpharmaceut.7b01096.10.1021/acs.molpharmaceut.7b01096 ↗
92. Kankala RK, Han Y-H, Xia HY, Wang SB, Zheng A. Nanoarchitectured prototypes of mesoporous silica nanoparticles for innovative biomedical applications. J Nanobiotechnol. 2022;20:126. https://doi.org/10.1186/s12951-022-01315-x.10.1186/s12951-022-01315-x ↗
93. Mohammadpour R, Cheney DL, Grunberger JW, Yazdimamaghani M, Jedrzkiewicz J, Isaacson KJ, Dobrovolskaia MA, Ghandehari H. One-year chronic toxicity evaluation of single dose intravenously administered silica nanoparticles in mice and their Ex vivo human hemocompatibility. J Control Release. 2020;324:471–81. https://doi.org/10.1016/j.jconrel.2020.05.027.10.1016/j.jconrel.2020.05.027 ↗
94. Clemments AM, Muniesa C, Landry CC, Botella P. Effect of surface properties in protein corona development on mesoporous silica nanoparticles. RSC Adv. 2014;4:29134–8. https://doi.org/10.1039/C4RA03277B.10.1039/C4RA03277B ↗
95. Lin CY, Yang CM, Linden M. Influence of serum concentration and surface functionalization on the protein adsorption to mesoporous silica nanoparticles. RSC Adv. 2019;9(58):33912–21. https://doi.org/10.1039/c9ra05585a.10.1039/c9ra05585a ↗
96. Resnik DB, Tinkle SS. Ethics in nanomedicine. Nanomedicine. 2007;2(3):345–50. https://doi.org/10.2217/17435889.2.3.345.10.2217/17435889.2.3.345 ↗
97. Gu B, Zhao Q, Ao Y. Advances in immunomodulatory mesoporous silica nanoparticles for inflammatory and cancer therapies. Biomolecules. 2024;14(9): 1057. https://doi.org/10.3390/biom14091057.10.3390/biom14091057 ↗
98. Marcelo GA, Galhano J, Robalo TT, Cruz MM, Marcos MD, Manez RM, Duarte MP, Martinez JLC, Lodeiro C, Oliveira E. Magneto-fluorescent mesoporous nanocarriers for the dual-delivery of Ofloxacin and Doxorubicin to tackle opportunistic bacterial infections in colorectal cancer. Int J Molecular Sci. 2022;23(20):12287. https://doi.org/10.3390/ijms232012287.10.3390/ijms232012287 ↗
99. Patra JK, Das G, Fraceto LF, Campos EVR, del Pilar Rodriguez-Torres M, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin HS. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16: 71. https://doi.org/10.1186/s12951-018-0392-8.10.1186/s12951-018-0392-8 ↗
100. Mishra A, Qamar F, Ashrafi K, Fatima S, Samim M, Mohmmed A, Abdin MZ. Emerging nanotechnology-driven drug delivery solutions for malaria: addressing drug resistance and improving therapeutic success. Int J Pharm. 2025;670: 125163. https://doi.org/10.1016/j.ijpharm.2024.125163.10.1016/j.ijpharm.2024.125163 ↗